{"date":"2026-10-09","count":2,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6827-2026-10-09-1503-1l48i39","company_id":"6827","company":"巨生醫","market":"興櫃","industry":"生技醫療","date":"2026-10-09","time":"15:03:52","subject":"本公司新藥MPB-1523 MRI顯影劑-肝細胞癌向美國FDA申請進行第三期臨床試驗(計畫編號:IOP-CT-007)，已通過美國FDAIND 30天審查期，將啟動MPB-1523 三期臨床試驗。","clause":"第8款","fact_date":"2026-10-09","cite_as":"公開資訊觀測站重大訊息：巨生醫（6827），2026-10-09 15:03，「本公司新藥MPB-1523 MRI顯影劑-肝細胞癌向美國FDA申請進行第三期臨床試驗(計畫編號:IOP-CT-007)，」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6645-2026-10-09-1216-ois9r3","company_id":"6645","company":"金萬林-創","market":"上市","industry":"生技醫療","date":"2026-10-09","time":"12:16:40","subject":"公告本公司初次申請股票創新板上市時所出具之承諾事項暨其後續執行情形","clause":"第51款","fact_date":"2026-10-08","cite_as":"公開資訊觀測站重大訊息：金萬林-創（6645），2026-10-09 12:16，「公告本公司初次申請股票創新板上市時所出具之承諾事項暨其後續執行情形」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}